Innate Pharma (IPHA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $154.15M
Last updated: Nov 17, 2026 at 11:01 AM ET
Innate Pharma (IPHA) Financials: Revenue, Profit and Cash Flow
Innate Pharma reported revenue of EUR 2.79M for the fiscal year ended Dec 31, 2025, down 77.9% from the year before. That year, net income was EUR -49.18M with a net margin of -1764.5%, operating cash flow was EUR -32.56M and free cash flow was EUR -34.91M. The quarter ended Jun 30, 2026 had revenue of EUR 5.66M and net income of EUR -19.62M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue fell from EUR 56.16M, a compound annual decline of 28.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | 2.79M | -77.9% | 100.0% | -1916.9% | -1764.5% |
| Dec 2024 | 12.62M | -75.7% | 100.0% | -408.6% | -392.0% |
| Dec 2023 | 51.90M | -10.0% | 10.8% | -24.4% | -14.6% |
| Dec 2022 | 57.67M | +376.2% | 10.4% | -99.6% | -100.7% |
| Dec 2021 | 12.11M | -82.6% | -184.1% | -394.9% | -436.0% |
| Dec 2020 | 69.77M | +1.2% | 28.8% | 1.5% | -91.7% |
| Dec 2019 | 68.97M | -13.7% | 34.5% | -39.2% | -30.1% |
| Dec 2018 | 79.89M | +144.8% | 12.9% | 6.4% | 3.8% |
| Dec 2017 | 32.63M | -41.9% | -105.3% | -122.5% | -148.3% |
| Dec 2016 | 56.16M | N/A | 13.4% | 13.5% | 22.5% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.79M | 12.62M | 51.90M | 57.67M | 12.11M | 69.77M | 68.97M | 79.89M | 32.63M | 56.16M |
| Cost of revenue | N/A | 51.98M | 56.02M | 51.66M | 47.00M | 49.71M | 45.16M | 69.56M | 67.00M | 48.63M |
| Gross profit | 2.79M | 12.62M | 5.62M | 6.01M | -22.30M | 20.07M | 23.82M | 10.34M | -34.37M | 7.53M |
| Research and development | 43.62M | 51.98M | 56.02M | 51.66M | 47.00M | 49.71M | 1.60M | 69.56M | 67.00M | 48.63M |
| Operating income | -53.42M | -51.58M | -12.67M | -57.42M | -47.83M | 1.08M | -27.05M | 5.15M | -39.98M | 7.57M |
| Net income | -49.18M | -49.47M | -7.57M | -58.10M | -52.81M | -63.98M | -20.76M | 3.05M | -48.38M | 12.64M |
| EBITDA | -43.65M | -46.91M | -1.84M | -12.28M | -43.23M | 57.88M | 18.10M | 12.55M | -35.59M | 10.83M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.66M | -2.07M | -2.07M | 4.86M | 276.00K | 276.00K | 12.35M | 16.56M | 21.44M | 10.72M | 35.34M | 20.10M |
| Gross profit | 5.66M | 18.45M | 18.45M | -15.66M | 29.35M | 29.35M | -16.73M | -3.13M | -3.13M | -1.56M | 19.62M | 4.37M |
| Operating income | -19.01M | -28.00M | -28.00M | -25.43M | -25.26M | -25.26M | -26.31M | -7.42M | -12.27M | -6.13M | -5.25M | -199.50K |
| Net income | -19.62M | -27.63M | -27.63M | -21.34M | -24.71M | -24.71M | -24.76M | -9.29M | -9.29M | -4.64M | 1.72M | 859.00K |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of EUR 22.48M by 5.60M. Shareholder equity was negative, at -21.69M, as total liabilities of 84.39M exceeded total assets of 62.69M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 62.69M | 111.06M | 175.19M | 207.86M | 267.50M | 307.42M | 401.36M | 451.22M | 255.02M | 281.58M |
| Current assets | 46.69M | 85.74M | 148.01M | 139.83M | 138.26M | 173.33M | 237.60M | 319.64M | 137.52M | 230.08M |
| Cash and equivalents | 28.08M | 66.40M | 70.61M | 84.22M | 103.76M | 136.79M | 202.89M | 152.31M | 99.37M | 175.91M |
| Total liabilities | 84.39M | 102.22M | 132.29M | 153.71M | 160.06M | 151.45M | 183.94M | 283.98M | 169.07M | 195.41M |
| Short-term debt | 8.80M | 8.71M | 8.94M | 2.10M | 30.75M | 2.14M | 2.13M | 1.35M | 1.34M | 1.26M |
| Long-term debt | 13.67M | 22.18M | 30.61M | 38.93M | 13.50M | 16.95M | 14.10M | 2.03M | 2.42M | 1.05M |
| Shareholder equity | -21.69M | 8.83M | 51.90M | 54.15M | 107.44M | 155.97M | 217.42M | 167.24M | 85.96M | 86.17M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 34.71M | 62.69M | 62.69M | 92.94M | 111.06M | 111.06M | 151.50M | 175.19M | 184.19M | 184.19M | 199.05M | 207.86M |
| Total liabilities | 75.20M | 84.39M | 84.39M | 87.79M | 102.22M | 102.22M | 122.70M | 123.29M | 132.29M | 132.29M | 141.19M | 153.71M |
| Cash and equivalents | 6.46M | 28.08M | 28.08M | 53.70M | 66.40M | 66.40M | 69.99M | 70.61M | 70.61M | 70.61M | 71.41M | 84.22M |
| Shareholder equity | -40.49M | -21.69M | -21.69M | 5.14M | 8.83M | 8.83M | 28.80M | 51.90M | 51.90M | 51.90M | 57.86M | 54.15M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -32.56M | -6.90M | -32.56M | -19.15M | -58.46M | -51.81M | 34.92M | -32.53M | -48.06M | -36.85M |
| Capital expenditures | 2.35M | 391.00K | 351.00K | 1.12M | 1.33M | 11.28M | 65.40M | 1.43M | 6.03M | 9.39M |
| Free cash flow | -34.91M | -7.29M | -32.91M | -20.28M | -59.79M | -63.09M | -30.48M | -33.96M | -54.09M | -46.24M |
| Investing cash flow | 20.63M | 9.20M | 20.63M | 1.88M | -917.00K | -13.37M | -62.12M | 24.28M | -29.46M | 60.51M |
| Financing cash flow | -1.97M | -6.01M | -1.97M | -1.83M | 26.82M | -1.14M | 77.77M | 61.22M | 915.00K | -602.00K |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -21.33M | -23.40M | -23.40M | -31.16M | -9.93M | -9.93M | 3.04M | -21.09M | -21.09M | -10.55M | -11.46M | -20.20M |
| Capital expenditures | 91.21K | 85.05K | 85.05K | 58.00K | 108.00K | 108.00K | 283.00K | 42.00K | 42.00K | 21.00K | 312.00K | 702.00K |
| Free cash flow | -21.42M | -23.48M | -23.48M | -31.22M | -10.04M | -10.04M | 2.75M | -21.14M | -21.14M | -10.57M | -11.78M | -20.91M |
Frequently Asked Questions About IPHA
What is Innate Pharma's annual revenue?
Innate Pharma reported revenue of EUR 2.79M for the fiscal year ended Dec 31, 2025.
How fast is Innate Pharma's revenue growing?
Revenue was down 77.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -63.6%.
Is Innate Pharma profitable?
No. Innate Pharma reported net income of EUR -49.18M for the fiscal year ended Dec 31, 2025, with a net margin of -1764.5%.
How much free cash flow does IPHA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of EUR -32.56M minus capital expenditures of EUR 2.35M produced free cash flow of EUR -34.91M.
How much debt does Innate Pharma have?
The balance sheet dated Dec 31, 2025 reported long-term debt of EUR 13.67M, short-term debt of EUR 8.80M and cash and equivalents of EUR 28.08M.
IPHA pages: Overview, Financials